[The treatment of patients with benign prostatic hyperplasia with Proscar MSD (finasteride)].
53 patients have undergone 1-year conservative treatment of benign prostatic hyperplasia with the drug proskar MSD. All the patients had the disease stage I-II, maximal urination rate at least 5 ml/s, residual urine to a maximum 150 ml. Benign nature of the disease was confirmed by the test with prostate-specific antigen. Selection of patients, follow-up and assessment of treatment results were conducted according to the scale of the International System of Overall Assessment of Prostatic Lesions. Proskar MSD was found active in benign prostatic hyperplasia basing on the shifts in the main three indices (symptom status, maximal urination rate, prostate size).
Stepanov
V N
VN
Teodorovich
O V
OV
Seregin
A V
AV
Kadyrov
Z A
ZA
D000368:Aged; D042944:Cholestenone 5 alpha-Reductase; D013196:Dihydrotestosterone / Q000037:antagonists & inhibitors*; D004341:Drug Evaluation; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life; D014563:Urodynamics / Q000187:drug effects
D013196:Dihydrotestosterone; D018120:Finasteride; D010088:Oxidoreductases; D042944:Cholestenone 5 alpha-Reductase
Lechenie bol'nykh s dobrokachestvennoĭ giperplazieĭ predstatel'noĭ zhelezy proskarom MSD (finasterid).